New formulations of drugs in epilepsy

Abstract

The advent of numerous new treatment options in epilepsy therapy over the last decade is enabling a more flexible and individualised approach to patients with seizures. For some patients, these products offer added efficacy, reduction of troublesome side effects associated with standard anticonvulsants, and control over acute seizure exacerbations. This review profiles new formulations of anti-epileptic drugs. Tegretol-XR^® (TXR) and Carbatrol^® (CBTL), two extended-release preparations of carbamazepine (CBZ), which allow twice daily administration, minimising drug toxicity and improving efficacy. Topiramate sprinkles and lamotrigine chewable dispersible tablets allow easier administration in children. The rectal gel preparation of diazepam (Diastat^®) is useful for parents of patients with acute seizure exacerbations. Intravenous valproate (Depacon^®) and fosphenytoin (Cerebyx^®) provide parenteral treatment of acute seizures, without sedation or significant peripheral venous side effects. All of these new formulations expand treatment options for patients with epilepsy, who will benefit from them.

• anti-epileptic drugs
• epilepsy
• extended release carbamazepine
• fosphenytoin
• intravenous valproate
• lamotrigine
• rectal diazepam
• topiramate